Japanese pharmaceutical giant Takeda Pharmaceutical Co. Ltd. announced a complete withdrawal from all cell therapy research and development activities. The company will seek external partners to advance its existing research platforms and clinical-ready programs as it pivots investment toward small molecule, biologics, and antibody-drug conjugate pipelines that promise faster delivery of transformative therapies. This strategic reprioritization follows years of effort in cell therapy but responds to financial pressures and the challenging funding environment in the field. Takeda highlighted that no clinical trials in cell therapy are currently ongoing, and it expects to take a significant impairment charge related to these assets.